Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Lucyna Kepka"'
Autor:
Zhengfei Zhu, Jianjiao Ni, Xuwei Cai, Shengfa Su, Hongqing Zhuang, Zhenzhou Yang, Ming Chen, Shenglin Ma, Conghua Xie, Yaping Xu, Jiancheng Li, Hong Ge, Anwen Liu, Lujun Zhao, Chuangzhou Rao, Congying Xie, Nan Bi, Zhouguang Hui, Guangying Zhu, Zhiyong Yuan, Jun Wang, Lina Zhao, Wei Zhou, Chai Hong Rim, Arturo Navarro-Martin, Ben G. L. Vanneste, Dirk De Ruysscher, J. Isabelle Choi, Jacek Jassem, Joe Y. Chang, Lucyna Kepka, Lukas Käsmann, Michael T. Milano, Paul Van Houtte, Rafal Suwinski, Alberto Traverso, Hiroshi Doi, Yang-Gun Suh, Georges Noël, Natsuo Tomita, Roman O. Kowalchuk, Terence T. Sio, Baosheng Li, Bing Lu, Xiaolong Fu
Publikováno v:
Translational Lung Cancer Research, 11, 1763-1795. AME Publishing Company
Background: Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has historically served as a palliative modality in metastatic NSCLC, considerable a
Autor:
Zhenyang, Zhang, Shuhan, Xie, Weijing, Cai, Zhi-Nuan, Hong, Chuangcai, Yang, Yukang, Lin, Jiafu, Zhu, Zhiwei, Lin, Daniel C, Christoph, Hanibal, Bohnenberger, Lucyna, Kepka, Wolfgang M, Brueckl, Paul, Van Houtte, Mingqiang, Kang, Jiangbo, Lin
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Large part of patients of stage IB non-small cell lung cancer (IB NSCLC) may suffer recurrence after surgery. This study is to determine risk factors and establish a nomogram for postoperative recurrence and to provide a reference for adj
Publikováno v:
J Thorac Dis
In non-small cell lung cancer (NSCLC) brain metastases (BM) will affect up to 50% of patients during whole disease period. BM themselves impact heavily not only on patient’s prognosis but also are a source of symptoms aggravating quality of life. S
Autor:
Lucyna Kepka
Publikováno v:
J Thorac Dis
Publikováno v:
J Thorac Dis
The incidence of brain metastases (BM) is continuing to grow in the elderly population with lung cancer, but these patients are seriously under-represented in clinical trials. Thus, their treatment is not based on the evidence from randomized prospec
Publikováno v:
J Thorac Dis
Management of brain metastases (BM) from small-cell lung cancer (SCLC) is complex and not supported by a strong evidence from prospective clinical trials. Owing to the different clinical and pathological characteristics of SCLC, patients with this hi
Autor:
Lucyna Kepka, Joanna Socha
Publikováno v:
Transl Lung Cancer Res
In the field of radiotherapy (RT), the issues of total dose, fractionation, and overall treatment time for non-small cell lung cancer (NSCLC) have been extensively investigated. There is some evidence to suggest that higher treatment intensity of RT,
Autor:
B. Uziębło-Życzkowska, M. Mielniczuk, P. Pawłowski, Lucyna Kepka, J. Chałubińska-Fendler, M. Maciorowska, A. Rygielska, Dobromira Tyc-Szczepaniak, Joanna Socha, A. Jurek
Publikováno v:
Radiotherapy and Oncology. 161:S975-S977
Autor:
Krzysztof Bujko, Andrzej Rutkowski, Lucyna Pietrzak, Marek Szczepkowski, Lucjan Wyrwicz, Wojciech Polkowski, Wojciech Michalski, Roman Styliński, Jacek Krynski, Jacek Zwolinski, Bogumiła Ciseł, G. Nawrocki, Malgorzata Jankiewicz, Wiesław Tarnowski, Lucyna Kepka, Rafał Sopyło, Ewa Kosakowska
Publikováno v:
Rep Pract Oncol Radiother
Aim To evaluate the role of oxaliplatin in neoadjuvant chemotherapy delivered after short-course irradiation. Background Using oxaliplatin in the above setting is uncertain. Patients and methods A subgroup of 136 patients managed by short-course radi
Publikováno v:
Radiotherapy and Oncology. 148:174-180
Introduction We report the results of toxicity and survival in stage III NSCLC patients treated with concurrent accelerated hypofractionated AHRT–CHT within a prospective study. Methods 92 patients received 3D-CRT or IMRT-planned RT: 58.8 Gy /21 fr